-
介质释放,介质释放 Novartis meets all tender offer conditions to acquire MorphoSys AG for EUR68 per share in cash Novartis secured79.6 percent acceptance by MorphoSys shareholders during the initial acceptance period,reaching the minimum 65%acceptance thresholdSettlement of the shares tendered during the… -
介质释放,介质释放 Novartis highlights pioneering innovation in CML with data from Scemblix ® Phase III ASC 4 FIRST study in newly diagnosed patients at ASCO and EHA Primary results of the Scemblix ® ASC4FIRST pivotal Phase III study in first-line Ph+CML-CP supporting third USFDA Breakthrough Therapy designation,to be detailed in the ASCO Press Program and the… -
Pulse Update Novartis receives FDA Breakthrough Therapy designation for Scemblix ® in1L CML -
介质释放,介质释放 Novartis enters agreement to acquire Mariana Oncology,strengthening radioligand therapy pipeline Transaction reinforces company’s strategic focus on developing next-generation treatment options for patients living with cancer Mariana Oncology is a preclinical-stage biotechnology company focused… -
存储,存储 People and Culture From black holes to AI driven drug discovery–collaboration wins the day Dr Bülent K 栏的“字体”框中的字体)的可选字体名称 z 栏的“字体”框中的字体)的可选字体名称 人工和计算机科学技术 -
介质释放,介质释放 地下Venture announce positive efficicacy and safety data for annovel treatment for babies<5kg with malaria There is currently no evidence-based treatment for the smallest babies with malaria The CALINA study tested a new ratio and dose of Coartem ® (artemether-lumefantrine)to account for metabolic… -
介质释放,介质释放 Novartis radioligand therapy Lutathera ® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors Approval based on NETTER-Ptrial in which Lutathera demonstrated a consistent safety profile and comparable drug exposure between pediatric(ages12-17)and adult patients Gastroenteropancreatic… -
Featured News Novartis Financial Results–Q12024 Novartis announced the company’s financial results for the first quarter of 2024。 -
关键帧Release Novartis delivers double-digit sales growth and core margin expansion in Q1; FY2024 guidance raised Ad hoc announcement pursuant to Art.53LQ1net sales grew+11%(cc1,+10%USD)with core operating income up+22%(cc,+16%USD)Key growth drivers continued strong sales momentum including… -
介质释放,介质释放 Novartis Kesimpta ® six-year efficicacy data show substantial benefits in recently diagnosed treatment-naïve people with relapsing multiple sclerosis Continuous Kesimpta ® treatment for up to six years showed sustained efficicacy in recently diagnosed(≤3 years)treatment-native people living with relapsing multiple sclerosis(RMS)in an analysis… -
介质释放,介质释放 新建Novartis Fabhalta ® (iptacopan)data show clinically meaningful and statistically significant proteinuria reduction of 38.3%versus placebo for patients with IgA nephropathy(IgAN) APPLAUSE-IgAN is first and only Phase III study to demonstrate significant proteinuria reduction by targeting the complement system in patients with IgAN1IgAN is aheterogeneous,progressive,rare… -
介质释放,介质释放 Novartis tender offer for MorphoSys AG commences Basel,April112024–Novartis published today the offer document for the voluntary public takeover offer byits wholly owned subsidiary Novartis BidCo AG for all outstanding shares of MorphoSys AG…
-
介质释放,介质释放 Novartis meets all tender offer conditions to acquire MorphoSys AG for EUR68 per share in cash Novartis secured79.6 percent acceptance by MorphoSys shareholders during the initial acceptance period,reaching the minimum 65%acceptance thresholdSettlement of the shares tendered during the… -
介质释放,介质释放 Novartis highlights pioneering innovation in CML with data from Scemblix ® Phase III ASC 4 FIRST study in newly diagnosed patients at ASCO and EHA Primary results of the Scemblix ® ASC4FIRST pivotal Phase III study in first-line Ph+CML-CP supporting third USFDA Breakthrough Therapy designation,to be detailed in the ASCO Press Program and the… -
介质释放,介质释放 Novartis enters agreement to acquire Mariana Oncology,strengthening radioligand therapy pipeline Transaction reinforces company’s strategic focus on developing next-generation treatment options for patients living with cancer Mariana Oncology is a preclinical-stage biotechnology company focused… -
介质释放,介质释放 地下Venture announce positive efficicacy and safety data for annovel treatment for babies<5kg with malaria There is currently no evidence-based treatment for the smallest babies with malaria The CALINA study tested a new ratio and dose of Coartem ® (artemether-lumefantrine)to account for metabolic… -
介质释放,介质释放 Novartis radioligand therapy Lutathera ® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors Approval based on NETTER-Ptrial in which Lutathera demonstrated a consistent safety profile and comparable drug exposure between pediatric(ages12-17)and adult patients Gastroenteropancreatic… -
关键帧Release Novartis delivers double-digit sales growth and core margin expansion in Q1; FY2024 guidance raised Ad hoc announcement pursuant to Art.53LQ1net sales grew+11%(cc1,+10%USD)with core operating income up+22%(cc,+16%USD)Key growth drivers continued strong sales momentum including… -
介质释放,介质释放 Novartis Kesimpta ® six-year efficicacy data show substantial benefits in recently diagnosed treatment-naïve people with relapsing multiple sclerosis Continuous Kesimpta ® treatment for up to six years showed sustained efficicacy in recently diagnosed(≤3 years)treatment-native people living with relapsing multiple sclerosis(RMS)in an analysis… -
介质释放,介质释放 新建Novartis Fabhalta ® (iptacopan)data show clinically meaningful and statistically significant proteinuria reduction of 38.3%versus placebo for patients with IgA nephropathy(IgAN) APPLAUSE-IgAN is first and only Phase III study to demonstrate significant proteinuria reduction by targeting the complement system in patients with IgAN1IgAN is aheterogeneous,progressive,rare… -
介质释放,介质释放 Novartis tender offer for MorphoSys AG commences Basel,April112024–Novartis published today the offer document for the voluntary public takeover offer byits wholly owned subsidiary Novartis BidCo AG for all outstanding shares of MorphoSys AG… -
介质释放,介质释放 新Novartis data show early addition of twice-yearly*Leqvio ® (inclisiran)following maximally tolerated statin therapy significantly reduces LDL-cin ASCVD patients in real-world setting V-INITIATE trial demonstrates that early initiation with Leqvio,prior to guideline-recommended ezetimibe,for ASCVD patients unable to achieve LDL-C goal on statin therapy alone led to significant… -
介质释放,介质释放 Novartis Fabhalta ® (iptacopan)receives positive CHMP opinion as first oral monotherapy for adult patients with paroxysmal nocturnal hemoglobinuria(PNH) 定位CHMP opinion based on robust Phase III data,including APPLY-PNH,demonstrating superior hemoglobin improvement in the absence of transfusions with Fabhalta compared to anti-C5 therapy1-5If… -
介质释放,介质释放 Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting Shareholders approve27th consecutive dividend increase to CHF3.30(+3.1%)per share for2023; representing a3.7%yield1and approximately58%payout of free cash flowShareholders confirm Joerg…
-
关键帧Release Novartis delivers double-digit sales growth and core margin expansion in Q1; FY2024 guidance raised Ad hoc announcement pursuant to Art.53LQ1net sales grew+11%(cc1,+10%USD)with core operating income up+22%(cc,+16%USD)Key growth drivers continued strong sales momentum including… -
关键帧Release Starkes Jahresergebnis:Novartis steigert den Nettoumsatzum10%,das operative Kernergebnis um18%(kWk ➋) sowie die Margen.Weiter Innovationsdynamik mit mehreren positiven Phase-3-Ergebnissen Ad-hoc-Mitteilung gemäss Art.53KR Geschäftsjahr(fortzuführende Geschäftsbereiche2)Der Nettoumsatz wuchs um+10%(kWk,+8%USD),unddas operative Kernergebnis verbesserte sicum+18%(… -
关键帧Release Novartis:forte performance en2023,hausse de10%du chiffre d’affaires net et de18%du résultat opérationnel core(tcc ➋), expansion de la marge.Innovation:nombreux résultats positifs de phase III Annonceévénementielle au sens de l’art。 53RCExercice complet(activités poursuivies2)Hausse de+10%(tcc,+8%USD)du chiffre d’affaires net et de+18%(tcc,+11%USD)du… -
关键帧Release Novartis delivers strong full year performance,10%net sales and 18%core operating income growth(cc) ➋), with margin expansion。 Continuing innovation momentum with multiple positive Ph3 readouts Ad hoc announcement pursuant to Art.53LRFull year(continuing operations2)Net sales grew+10%(cc,+8%USD)with core operating income growing+18%(cc,+11%USD)Sales growth was mainly driven by… -
关键帧Release Novartis Scemblix ® shows superior major molecular response(MMR)rates vs.standard-of-care TKIs in Phase III trial for newly diagnosed patients with chronic myeloid leukemia EDIA&INVESTOR RELEASE Novartis Scemblix ® shows superior major molecular response(MMR)rates vs.standard-of-care TKIs in Phase III trial for newly diagnosed patients with chronic… -
关键帧Release Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and statistically significant proteinuria reduction in patients with C3glomerulopathy(C3G) Ad hoc announcement pursuant to Art.53LR Phase III APPEAR-C3G study met its primary endpoint,demonstrating superiority of iptacopan vs.placebo in proteinuria reduction at six-month analysis1;… -
关键帧Release Novartis receives FDA approval for Fabhalta ® (iptacopan),offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH Ad hoc announcement pursuant to Art.53LR Approval based on APPLY-PNH trial in adults with PNH and anemia despite prior anti-C5treatment,and supported by the APPOINT-PNH study in complement… -
关键帧Release Novartis upgrades mid-term sales growth guidance,showcases its differentiated innovative medicines strategy and robust pipeline at R&D Day Ad hoc announcement pursuant to Art.53LR‘Pure-play’innovative medicines strategy focused on four therapeutic areas and five technology platforms,which offer potential for consistent… -
关键帧Release Novartis investigational atrasentan Phase III study demonstrates clinically meaningful and high ly statistically significant proteinuria reduction in patients with IgA nephropathy(IgAN) Ad hoc announcement pursuant to Art.53LR Phase III ALIGN study met its primary endpoint,demonstrating superiority of atrasentan vs.placebo in proteinuria reduction at36-week interim analysis1;… -
关键帧Release Novartis:hausse de12%du chiffre d’affaires et de21%du résultat opérationnel core(tcc ➋)。 Spin-off de Sandoz,étapes importantes de l’innovation; hausse des prévisions pour 2023 Annonceévénementielle au sens de l’art。 53RC Le spin-off de Sandoz parachève la spécialisation d’Innovative Medicines dans les médicaments innovants le commentaire ci-dessous concerne les… -
关键帧Release Novartis steigert Umsatzum12%und operatives Kernergebnis um21%(fortzuführende Geschäftsbereiche,kWk ➋)。 Sandoz abgespalten,wichtige Innovationsmeilesteine erreicht und Prognose2023erhöht Ad-hoc-Mitteilung gemäss Art.53KR Die Transformation zueinem Unternehmen,das rein auf innovative Medikamente spezialisiertist,wurde mit dem Spin-off von Sandoz abgeschlossen; die… -
关键帧Release Novartis delivers12%sales and 21%core operating income growth from conting operations(incc) ➋)。 Executes Sandoz spin-off,achieves important innovation milestones,and raises FY2023 guidance Ad hoc announcement pursuant to Art.53LR Transformation into a“pure-play”innovative medicines business is complete,with the spin-off of Sandoz; commentary below is on continuing…
-
Featured News Novartis Financial Results–Q12024 Novartis announced the company’s financial results for the first quarter of 2024。 -
Featured News Novartis 2023 Financial Results Novartis announces the company’s fourth quarter and 2023full year financial results。 -
Featured News J.P.Morgan Healthcare Conference 2024 Latest news and interviews for media and investors -
Featured News Our next era Novartis poised to expand impact on human health as it begins next era。 -
Featured News Novartis Financial Results–Q3 2023 -
Featured News Novartis’Giving&Volunteering wins ACCP’s2023 Corporate Social Impact Team of the Year Award -
Featured News Novartis Financial Results–Q2 2023 Novartis announced the company’s financial results for the second quarter and first half of 2023。 -
Featured News Novartis Financial Results–Q12023 Novartis announced the company’s financial results for the first quarter of 2023。 -
Featured News Novartis 2022 Financial Results Novartis announces the company’s fourth quarter and 2022full year financial results。 -
Featured News World Economic Forum 2023 -
Featured News Creating positive social change through voluntering Over1billion people volunter worldwide,sharing their skills and experience,providing support within their communities,and offering emergency assistance to those in need。 On International Volunteer Day(December5),we join forces with the UN to recognize the tireless work of all volunters and the contributions that they make。 -
Featured News Novartis Financial Results–Q3 2022
-
状态,状态 Violence against innocent people runs counter to our work to improve human health -
状态,状态 Novartis condemns the terrorist actions against people in Israel and loss of innocent lives -
状态,状态 Novartis statement on collaboration and license agreement fortislelizumab with BeiGene,Ltd。 Novartis and BeiGene,Ltd.have mutually agreed to terminate the collaboration and license agreement fortislelizumab,ahumanized IgG4anti-PD-1monoclonal antibody。 -
状态,状态 无人值守设备支持系统 -
状态,状态 GT005(PPY988):Development Program in Geographic Atrophy -
状态,状态 充气再生Act lawsuit在Novartis statement on filing of Inflation Reduction Act lawsuit -
状态,状态 Novartis statement about Entrest ® (sacubitril/valsartan)选择(Medicare Drug Price Negotiation Program) -
状态,状态 European Commission(EC)adopts decision endorsing CHMP recommendation to revoke the conditional marketing authorization for Adakveo ® (crizanlizumab) -
状态,状态 CHMP recommends revoking the conditional marketing authorization for Adakveo ® (crizanlizumab) -
状态,状态 不受影响,不受影响 On February24,we marked the first anniversary of the war in Ukraine。 Novartis continues to condemn the ongoing conflict,while our unwavering support to those impacted continues through humanitarian aid,financial donations and critical medicines。 -
状态,状态 美国1 million for people in Turkey and Syria,and launches employee donation and voluntering programs -
状态,状态 不受影响,不受影响,不受影响
-
Pulse Update Novartis receives FDA Breakthrough Therapy designation for Scemblix ® in1L CML -
Pulse Update Novartis implements manufacturing adjustments for ribociclib to ensure alignment with latest regulatory standards in eBC by end of Q2 -
Pulse Update Novartis confirms plans to file for Pluvicto ® Pre-taxane label expansion in H2024 based on latest data from Phase III PSMAfore study -
Pulse Update Novartis appoints Sloan Simpson as Global Head of Investor Relations -
Pulse Update Novartis shares strategy and growth update at J.P.Morgan Healthcare Conference2024 -
Pulse Update FDA approves Novartis Millburn facility for US commercial production of Pluvicto ® -
Pulse Update Novartis completes FDA filing for approval of Millburn facility to support Pluvicto ® launch -
Pulse Update Novartis shares strategy insights and highlights key pipeline catalysts at JP Morgan Healthcare Conference 2023 -
Pulse Update Novartis receives FDA Fast Track designation for branaplam(LMI070)for the treatment of Huntington’s Disease -
Pulse Update FDA grants Priority Review for investigational targeted radioligand therapy177Lu-PSMA-617 for patients with metatic castration-resistant prostate cancer(mCRPC) -
Pulse Update CIRRUS-1study of CFZ533(iscalimab)inkidney transplant patients -
Pulse Update Novartis receives FDA fast track designation for LNA043 in osteoarthritis of the knee
-
存储,存储 People and Culture From black holes to AI driven drug discovery–collaboration wins the day Dr Bülent K 栏的“字体”框中的字体)的可选字体名称 z 栏的“字体”框中的字体)的可选字体名称 人工和计算机科学技术 -
存储,存储 从上方向,从下方向 车辆驾驶室,车辆驾驶室,车辆驾驶室 State-of-the-art Novartis manufacturing facility in Indianapolis fortifies the foundation of an entirely new paradigm in pharmaceutical drug delivery。 -
存储,存储 Patient Perspectives Listening to the CML patient community Improving the patient experience and removing potential barriers to clinical trial participation -
存储,存储 People and Culture How collaboration can enhance your science career Kumar Veerapen,Senior Expert I Data Science -
存储,存储 Patient Perspectives Giving voice to people with a misunderstood disease Shanelle Gabriel was diagnosed with lupus—achronic autoimmune disease that mostly affects women of African American and Hispanic descent—while she was at college。 Today,as a singer,poet and advocate,she uses her voice to highlight challenges faced by people living with this complex and often misunderstood condition。 Photos: Brent Stirton,Getty Images for Novartis -
存储,存储 发现,发现 水项目再利用指数 Novartis is aiming for water neutrality in our own operations by2030。 India,we are contributing to this goal through a project near Hyderabad with anonprofit organization。 By tackling both water scarcity and the deprivation it causes,the project has revived the community。 Photos: Bjoern Myhre,Novartis -
存储,存储 访问到标题 A partnership against epilepsy Parts of Cameroon have rates of epilepsy that are among the highest in the world。 Despite the availability of effective therapies,poverty,alack of medical resources and superstition about the causes of epilepsy often lead to inadequate treatment and social exclusion for people living with the neurological condition。 Novartis is working with a Catholic mission on the ground in a central part of the country to overcome these barriers and improve care。 Photos: Bjoern Myhre,Novartis -
存储,存储 Patient Perspectives 炉膛炉膛炉膛的间隙 When Laurie Brunner found a lump in her breast just before Thanksgiving in 2018,it was the beginning of one of the most difficult periods of her life。 Although treatment put her cancer into remission,she found herself dealing with an emotional toll thaffects many survivors of early-stage breast cancer:the fear of it coming back。 Photos: Brent Stirton,Getty Images for Novartis -
存储,存储 People and Culture Balancing family life with a legal carer -
存储,存储 发现,发现 Innovation fueled by compassion We're striving to help more people with chronic spontaneous urticaria—askin condition marked by hives and distressful itching—return to their daily lives。 -
存储,存储 Patient Perspectives 外壳到外壳 People with breast cancer need better medicines that help reduce the risk and anxiety of it returning。 -
存储,存储 访问到标题 可移动式通风机 Sharing Key Insights and Lessons to Accelerate Progress。